0.5?l=proekt-po-tehnologii-postroy-taburet 2014-12-17T13:51:19+00:00 weekly. 6/berten.php?l=pravilnaya-prezentaciya-proekta 2014-04-28T20:44:02+00:00. Dec 08, 2011 Irinotecan is a pro-drug that is activated by carboxylesterases into the active metabolite, SN-38 (7-ethyl-10-hydroxyl-camptothecin) [1]. Irinotecan treats multiple solid tumors [2] by targeting topoisomerase I and resulting in double-stranded DNA breaks [3].
The goal of this study is to determine whether treatment with methylselenocysteine (MSC) results in differential uptake of irinotecan and its active metabolite (SN-38) between tumors of head and neck squamous cell carcinomas and normal tissue. The in vivo synergy between MSC and irinotecan is influenced by treatment schedule and associated with enhancement of tumor vessel maturation, intra-tumor concentration of SN-38 and apoptotic death of tumor cells. Normal tissue drug concentrations of were not impacted by selenium treatment. The finding is of clinical relevance for enabling the delivery of higher doses of irinotecan to reverse tumor resistance, recurrence and ultimately enhancing cure rates.
Introduction Irinotecan is a pro-drug that is activated by carboxylesterases into the active metabolite, SN-38 (7-ethyl-10-hydroxyl-camptothecin) []. Irinotecan treats multiple solid tumors [] by targeting topoisomerase I and resulting in double-stranded DNA breaks []. Methylselenocysteine (MSC) is a selenium containing compound that is activated by β-lyase into the active metabolite methylselenol []. MSC has modest partial response of anti-tumor activity when given alone.
However, MSC enhances the anti-tumor activity (cure rates) of irinotecan against FaDu and A253 xenografts []. FaDu and A253, head and neck squamous cell carcinomas (HNSCC), were previously characterized []. FaDu is poorly differentiated and p53 mutant.
A253 is well differentiated and null p53. Both untreated tumors have similar level of carboxylesterase-2, irinotecan activating enzyme []. In nude mice bearing human FaDu xenografts, sequential combination treatment of MSC (0.2mg/d × 28) and irinotecan (100mg/kg/wk × 4) increased the complete response (CR) rate from 30% after irinotecan alone to 100% after the combination treatment []. The CR rate increased from 10% after irinotecan alone to 60% after the combination treatment in mice bearing A253 xenografts. Treatment with MSC alone resulted in 30% partial response (PR) but 0% CR. Optimal therapeutic selectivity is achieved only when MSC is administered at least 7 days prior to irinotecan and continued throughout treatment schedule []. Kartoteka igr eksperimentov s vodoj. In our previously published study [], we demonstrated that the enhanced CR rates of HNSCC xenografts after combination treatment of MSC and irinotecan were due to multi-factorial alterations.